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The chemokines CCL17 (TARC) and CCL22 (MDC) function through the same receptor, CCR4, but have been
proposed to differentially affect the immune response. To better understand the role of the individual ligands, a
panel of rat anti-mouse CCL17 surrogate antibodies was generated that can be used to differentiate CCL17 and
CCL22 function in vitro and in vivo. We have successfully identified a panel of neutralizing antibodies by screening
hybridomas for the ability to inhibit CCL17-mediated calcium mobilization. Chemotaxis in response to CCL17 is
also inhibited, providing further evidence that the antibodies in this panel are antagonistic. Using a recombinant
cell line expressing human CCR4, we show that the antibodies block b-arrestin recruitment as evidence that the
antibodies are specifically blocking CCL17 signaling through CCR4. The antibodies within this panel inhibit
calcium mobilization with varying potency in the calcium flux assay, having apparent IC50 ranging from ap-
proximately 1 to > 400ng/mL. Although both CCL17 and CCL22 function through CCR4, only a single antibody
was identified as having detectable binding to CCL22. This panel of CCL17-specific antibodies provides tools that
can be used to differentiate CCL17 and CCL22 function through CCR4 interaction in vitro and in vivo.
Introduction
T he only known ligands for the chemokine receptorCCR4 are CCL17 (TARC) and CCL22 (MDC); binding of
each elicits distinct consequences.(1,2) CCL22 binds CCR4with
a higher affinity than does CCL17, which may correlate with
the differences in CCR4+ cell responses to the two chemo-
kines.(1,3) In vitro data have demonstrated that CCL22 has a
higher capacity to hold CCR4-expressing cells in place
whereas CCL17 has a tendency to permit movement of cells
along a gradient, suggesting that these two chemokines have
the potential to differentially establish chemotactic gradi-
ents.(4) Even interaction with CCR4 reveals differences be-
tween the two chemokines in that CCL22 binding readily
induces receptor internalization whereas CCL17 interaction
with CCR4 mediates internalization poorly.(5,6)
At the organismal level, CCL22 has been shown to be in-
strumental in promoting innate immunity in the response to
ceacal ligation and puncture (CLP) in the murine model of
experimental sepsis, whereas CCL17 seems to interfere with
innate immunity, actually promoting hepatic damage in con-
ditions of systemic LPS.(7,8) CCL22 and CCL17 also have op-
posing effects on Treg homeostasis in that CCL22 favors Treg
recruitment whereas CCL17 has been reported to favor more
pro-inflammatory conditions, converting the Treg phenotype
to an inflammatory mediator.(9,10) Studies in the CCL17–EGFP
mice in which the enhanced green flourescent protein (EGF)
coding region was used to disrupt CCL17 expression implicate
CCL17 as a major factor in initiating the inflammatory re-
sponse, establishing a role for CCL17 in contact hypersensi-
tivity.(9,11) CCR4 knockoutmice have also been used as ameans
to inhibit function of CCL17 and CCL22 but data from studies
in these mice is incongruent.(12,13) Treatment with a CCR4 an-
tagonist hasmetwith some success inmousemodels; however,
platelets also express CCR4, which could introduce con-
founding variables to these studies.(14,15) The ability to target
the individual ligands in vivo using neutralizing antibodies
provides the opportunity to better understand how each of
these molecules contributes to the immune response.
Current data from in vivo CCL17 blocking studies reported
in the literature have been generated using commercially
available polyclonal antibodies or rat monoclonal anti-CCL17
antibody in mouse models of disease. Neutralizing CCL17 by
administration of polyclonal antibody in the murine Asper-
gillus fumigatusmodel of asthma conferred enhanced survival
compared to mice receiving control antibody.(8) These results
strongly suggest that the polyclonal antibody is neutralizing
CCL17 function; however, polyclonal antibodies often are
promiscuous, making it difficult to be certain that the effects
are exclusively the result of CCL17 neutralization. In order to
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further explore the role of CCL17 in vivo, we generated
monoclonal surrogate antibodies and expressed them as chi-
meric molecules having rat VL and VH fusedwithmouse IgG1
Fc. The monoclonal antibodies that have been generated
effectively inhibit CCL17 function in vitro by blocking CCL17-
mediated effects on calcium mobilization, chemotaxis, and
b-arrestin recruitment through CCR4 interaction.
Materials and Methods
Expression of muCCL17 in Escherichia coli
BL21 (DE3)
E. coli were transformed with the Novagen pET24d vector
(EMD Millipore, Billerica, MA) expressing full-length mouse
CCL17 (A1 to P70) or expressing full-length human CCL17
(A2 toS71); the human protein was expressed with a SUMO
tag at the N-terminus. Cells were then cultured in 2-YT me-
dium containing 10 mg/mL kanamycin. Protein expression
was induced overnight at 37Cwith shaking at 250 rpm, using
IPTG at a final concentration of 1mM. The induced culture
was harvested by centrifugation at 4C, 5000 rpm for 15min.
Isolation of inclusion bodies. The cell pellet was re-
suspended in disruption buffer (20mM Tris [pH 8.0], 5mM
EDTA) then disrupted using a microfluidizer. The inclusion
bodies were collected by centrifugation at 5000 rpm for
20min, then washed with 20mM Tris, 5mM EDTA, and 1%
Triton X-100.
Solubilization of inclusion bodies. Inclusion bodies were
solubilized using 8M urea, 5mM EDTA, 20mM Tris HCl (pH
7.0), and 10mM DTT incubated at room temperature with
constant for 3 h. The solubilized inclusion bodies were clarified
by centrifugation at 4C, 18000g for 10min and then loaded
onto an SPFF XK26/15 column (GE Healthcare Bio-Sciences,
Piscataway, NJ) at a flow rate of 1mL/min. The column was
then washed with Buffer A (10mM potassium phosphate [pH
6.8], 8Murea) until a flat baselinewas achieved. For the elution
of the protein, a gradient of 0–100% B (Buffer A plus 1MNaCl)
over 6 CV was applied at a flow rate of 8mL/min.
Refolding. Refolding was initiated by diluting pooled
fractions with refolding buffer at a final concentration of 0.1M
NaHCO3, 1.5M guanidine HCl, 3mM cysteine, and 0.3mM
cystine. Refolding was allowed to proceed at room tempera-
ture for 48 h with gentle stirring followed by incubation in
cold room for 66 h.
Hybridoma generation
Rats (CD1) were immunized with purified recombinant
mouse CCL17. Following final boost, splenocytes from one rat
were harvested and prepared for fusion.
Lymphocytes were fused at a 1:1 ratio with FO murine
myeloma cells according to themethod of de St. Groth.(16) The
cells were resuspended in HAT medium, then plated in 96-
well flat-bottom plates. The plates were incubated in a hu-
midified 37C at 6% CO2 for 7 to 10 days.
Hybridoma culture supernatants were aspirated and re-
placed with fresh media 7 days after fusion, then screened
for antibody production by ELISA on day 10. To screen,
Nunc ELISA plates (cat#446612; ThermoFisher Scientific,
Waltham, MA) were coated with Goat anti-Rat IgG (Fc)
F(ab)’2 ( Jackson Immunoresearch, West Grove, PA) at 4mg/
mL in coating buffer (0.1M BupH Carbonate-bicarbonate
Buffer; ThermoFisher Scientific). Following overnight incu-
bation, wells were blocked using 0.4% BSA/PBS. Hy-
bridoma supernatants were added to the wells then
incubated for 30min. Plates were washed 3x with 0.2%
Tween-20/PBS. Biotinylated CCL17 or CCL22 was added
and allowed to incubate for 30min at room temperature.
After washing the plates, 3x streptavidin-HRP ( Jackson
Immunoresearch) was diluted 1:40,000 in 0.4% BSA/PBS,
then added to the wells and incubated for 30min at room
temperature. Plates were washed 3x with 0.2% Tween-20/
PBS before addition of SigmaFAST OPD substrate (Sigma-
Aldrich, St. Louis, MO). The plates were incubated at room
temperature for 15min and the reaction was stopped by
addition of 4N H2SO4. Results of the colorimetric reaction
were read using Powerwave HT340 at 490 nm and Gen5
software (both from BioTek, Winooski, VT).
Calcium flux assays
Calcium mobilization assay was performed using hy-
bridoma antibodies purified from culture supernatant using
Dynabeads Protein G (Invitrogen, Grand Island, NY) and
CCRF-CEM cell-human T lymphoblastic cell line. Briefly,
cells were cultured in RPMI with GlutaMAX, 10% FBS,
10mM Hepes, 1mM sodium pyruvate, 4500mg/L glucose,
and 1500mg/mL sodium bicarbonate at 37C incubator with
5% CO2. The cells were harvested by centrifugation, re-
suspended at 1.6 · 106 cells/mL, and seeded in 384-well
poly-D-lysine coated black view assay plate (Greiner Bio-
One, Monroe, NC) in the presence of Fluo-8 NW dye-loading
buffer (ABD Bioquest, Sunnyvale, CA); the buffer consists of
10mL Fluo-8 NW, 1mL 10x Pluronic F127 Plus, and 19mL
assay buffer with 0.1% BSA, which was allowed to incubate
at 37C with 5% CO2 for 30min. Purified hybridoma a-
CCL17 antibodies, MAB529 control antibodies, rat igG2a
isotype control MAB006 (latter two antibodies from R&D
Systems), or assay buffer was pre-incubated with mCCL17
for 60min at room temperature. Calcium mobilization was
assessed using FDSS 6000 (Hamamatsu, Bridgewater, NJ) to
measure the fluorescence intensity using 490 nm excitation
and 525 nm emission.
FIG. 1. Effect of purified hybridoma-generated anti-CCL17 antibodies on mouse CCL17 bioactivity. Hybridoma-generated
antibodies that were shown to bind CCL17 by ELISA were screened for inhibitors of CCL17 function using the calcium
mobilization assay. (A–D) Purified hybridoma antibodies, control anti-mouse CCL17 antibody, and rat IgG2a isotype con-
trols were pre-incubated in the presence or absence of 2 ng/mL mouse CCL17, then added to CCRF-CEM cells containing
Fluo-8 dye-loading buffer. Calcium mobilization was determined by measuring the florescence intensity. Controls are shown
to the left of each panel. Antagonist antibodies were defined as those that reduced florescent intensity to levels less than or
equal to 3 standard deviations of the mean of the fluorescence intensity seen with mouse CCL17 alone.
‰
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FIG. 1. Continued.
165
Antibody cloning and expression
The VH and VL region genes were cloned from each of
the rat hybridomas expressing a-mouse CCL17 antibodies.
The chimeric antibodies were expressed as mouse IgG1/k
antibodies in HEK 293 F cells. Purification of the chimeric
antibodies was performed using MabSelectSuRe (GE
Healthcare Bio-Sciences) and AKTAxpress followed by
elution using 0.1M sodium acetate (pH 3.5) and subsequent
dialysis into DPBS (pH 7.2). Endotoxin was removed using
ActiClean resin (Sterogene Bioseparations, Carlsbad, CA).
Quality and purity were assessed by SDS-PAGE and SEC
HPLC (TSKgel BioAssist G3SWXL, Tosoh Bioscience, King
of Prussia, PA).
Chemotaxis
The neutralizing activity of the surrogate panel was as-
sessed in a chemotaxis assay using EL4 cells, and compared to
effects of isotype control MAbs CNTO5516 (rat-mouse IgG1
chimeric), MAB006 (rat IgG2a), and MAB529 (latter two
MAbs from R&D Systems). Chemotaxis was induced using
mouse CCL17, and the migration of EL4 cells through a 5-mm
filter was assessed using a 96-well chemotaxis plate (Neuro
Probe, Gaithersburg, MD). Ligand and/or antibody were
added to the lower chamber and the antibody concentrations
ranged from 0.25 to 10 mg/mL. EL4 cells were washed with
PBS and suspended in RPMI containing 0.1% BSA at a density
of 0.5 · 106 cells/mL, and 70 mL of this cell suspension was
added to the upper chambers. The chemotaxis plates were
incubated for 60min in a 5% CO2-humidified incubator at
37C, and cells migrating across the membrane into the lower
chamber were measured using the Cell Titer-Glo Lumines-
cence Cell Viability Assay (Promega, Madison, WI).
b-arrestin assay
The b-arrestin recruitment assay was performed as de-
scribed previously using human CCR4 expressing CHO cells
and the PathHunter eXpress b-arrestin Human and Ortholog
GPCR assay (DiscoveRx, Fremont, CA), according to the
manufacturer’s recommendations. Mouse CCL17 was pre-
incubated in the presence or absence of a-CCL17 chimeric
antibody, a-CCL17 control antibodyMAB529 (R&DSystems),
or isotype control MAB006 (all from R&D Systems) for 20–
30min at 37C with 5% CO2 before the addition to cells. Fol-
lowing addition to the cells, the assay was allowed to proceed
for 90min. Chemiluminescent detection substrates were ad-
ded and incubated at room temperature for 60min. Lumi-
nescence readings were taken on the Victor3 V Wallac1420
Multilabel plate reader (Perkin Elmer, Shelton, CT) and ana-
lyzed on GraphPad Prism software (San Diego, CA). For dose
curves, concentration started at 1mMwith a 1:2 dilution series.
For antibody inhibition studies, mouse CCL17 was used at a
constant concentration of 30 nM.
Results
Generation and functional characterization of rat
anti-mouse surrogate antibodies
Hybridomas were generated by fusion of splenocytes pre-
pared from rats immunized with recombinant CCL17. A pa-
nel of 160 antibodies was identified by screening for CCL17
binding using a capture ELISA and these hybridomas were
scaled up for further evaluation in functional assays. Con-
firmation of CCL17 specificity following scale upwas done by
ELISA and subsequent cross-screening on mouse CCL22,
which identified only a single clone as having detectable
cross-reactivity for CCL22. All clones were further tested for
ability to inhibit CCL17 function.
The panel of 160 hybridomaswas screened for antibodies that
inhibit CCL17 function in a high throughput calcium flux assay
using human CCRF-CEM cells, which mobilize calcium in re-
sponse to stimulation with mouse CCL17.(17) Small-scale puri-
fication was performed on each antibody in the panel, and the
purified antibodies were incubated with recombinant mouse
CCL17 prior to addition to CCRF-CEM cells. Those antibodies
that blocked release of calcium to levels £3 standard deviations
of the mean as defined by treatment with CCL17 either alone or
in the presence of control antibodies were considered neutral-
izing (Fig. 1). Because these samples were from the primary
hybridoma cultures, there was insufficient material to perform
the assay using normalized concentrations for all samples so the
possibility exists that some potentially neutralizing cloneswould
be missed due to lower antibody concentration. Conversely,
there may also be clones having very high antibody concentra-
tions in the culture supernatant that would be tagged as neu-
tralizing when in fact the effect is an artifact of non-specific
binding. However, using this assay, we were able to identify 54
clones capable of neutralizing CCL17 functional activity.
Chimeric anti-CCL17 antibodies act as antagonists
for CCL17 signaling through CCR4
in dose-dependent manner
Subsequent characterization of the antagonistic properties
was conducted with chimeric antibodies in three functional
assays: calcium mobilization, chemotaxis, and b-arrestin re-
cruitment. To accommodate downstream in vivo studies, the rat
VH and VL regions were molecularly cloned and expressed as
chimeric mouse IgG1 antibodies. As a confirmatory assay to
demonstrate that these antibodies could inhibit CCL17 func-
tion, they were tested for the ability to block chemotaxis in
response to CCL17.(3,18) As shown in Figure 2, antibodies that
were initially identified as inhibitory in the calcium mobiliza-
tion screen as hybridoma supernatants also inhibited CCL17-
mediated chemotaxis of EL4 cells when expressed as chimeric
antibodies. Neither CCL17 specificity nor antagonistic activity
was lost upon conversion of the hybridoma antibodies from
fully rat antibodies to rat-mouse chimeric antibodies.
To confirm that the antibodies block CCL17 function
through CCR4, we next investigated whether any of the an-
tibodies would also inhibit b-arrestin recruitment. Chemo-
taxis mediated by CCL17 occurs through engagement of the
Gi coupled GPCR CCR4, which activates subsequent GPCR
signaling pathways, including recruitment of b-arrest-
in.(3,19,20) Since it had previously been determined that human
cells are responsive to murine CCL17 in the calcium flux as-
say, we reasoned that a human cell line–based reporter system
could be employed.(17) The antibodies were compared for
their ability to inhibit CCL17 function using a commercially
available cell line engineered to become luminescent when
signaling through CCR4 induces recruitment of b-arrestin.
Dose-response curves were performed for each of the anti-
bodies in the panel, thus allowing us to compare their
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FIG. 2. Chimeric anti-CCL17 antibodies that inhibit calcium mobilization also inhibit CCL17-mediated chemotaxis.
EL4 cells were incubated with 2 ng/mL mouse CCL17 in the presence and absence of each of the chimeric antibodies or
control antibodies. Data for control antibodies are as follows: positive control antibody (R&D MAb529) and corre-
sponding isotype control (Rat IgG2a,CNTO5516). Samples were run in triplicate and data are shown as the average – SD
for each condition.
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inhibitory activity (Fig. 3). The antibodies tested inhibited b-
arrestin recruitment in response to CCL17, indicating that we
are specifically blocking signaling through CCR4 in this sys-
tem. Of note, B220 appears to have a non-sigmoidal dose-
response curve in this assay. However, we have not reached a
plateau at the lower concentrations of antibody in this ex-
periment so the resulting dose-response curve is incomplete.
Expanding the range of antibody concentrations testedwould
most likely yield a sigmoidal curve in this assay.
That the anti-CCL17 antibodies differ in antagonistic ac-
tivity became evident from the dose-response data generated
in the b-arrestin recruitment assay. Although the antibodies
were originally identified as antagonistic by screening in a
calcium mobilization assay, this was performed using hy-
bridoma supernatants that were not concentration-normal-
ized. In this setting, the chances for discerning differences
between the antibodies are minimal at best. To determine
whether there was any correlation between antagonistic po-
tential in the calciummobilization assay and b-arrestin assay,
calcium mobilization was repeated using dose response
curves of the antibodies. In contrast to the b-arrestin assay,
differences in antagonistic activity among the antibodies were
not evident with respect to calciummobilization (Fig. 4). Most
of the antibodies have overlapping dose response curves that
fall into a relatively tight rangewith the exception of B226 and
to a limited degree B225 (Fig. 4A). The calcium mobilization
assay is appropriate for screening but does not provide the
level of sensitivity required to differentiate the antibodies
based on antagonistic activity.
Given that mouse CCL17 functions through human CCR4,
we reasoned that generation of cross-species binding anti-
bodies could be possible. However, because the overall
identity of the proteins is 64%, with 80% homology between
human and mouse CCL17, any cross-reactive antibodies
would most likely be less effective at blocking mouse CCL17
function. Out of the panel of 11 chimeric antibodies, a total of
five were identified as mouse-human cross-reactive by ELISA
(data not shown). Comparison of antagonistic effects on
mouse CCL17-mediated function between those antibodies
specific for mouse CCL17 and those that recognize both
mouse and human CCL17 in recruitment of b-arrestin show
that the mouse-human cross-reactive antibodies appear to
have IC50 within a relatively tight range (Fig. 3B). The same is
true for four of the six antibodies specific for mouse CCL17
(Fig. 3A); however, dose response curves for B225 and B220
are both shifted to the left of the majority. Similar results are
seen in the comparison of calcium mobilization data in that,
with the exception of B226 and possibly B225, the dose re-
sponse curves largely overlap (Fig. 4). Taken together, these
data suggest that there is no functional advantage for those
antibodies that bound both proteins; all the antibodies within
the panel could be demonstrated to inhibit mouse CCL17
function with comparable activity.
Discussion
The goal of this experiment was to generate tools that
would inhibit CCL17 function mediated by CCR4 interaction,
thus enabling future studies to understand CCL17-specific
effects on CCR4without impacting CCL22.Much information
regarding the receptor CCR4 in disease conditions has been
facilitated by availability of CCR4-knockout mice, but these
results are ligand-independent in that neither CCL17 nor
CCL22 are known to interact with any other receptors.(21)
Teasing out any differential effects associated with binding of
the individual ligands to CCR4 requires CCL17- and CCL22-
specific antibodies that lack cross-reactivity to both chemo-
kines. This panel of antibodies specific for CCL17 was
generated by producing hybridomas from immunized rats
followed by conversion of the antagonistic antibodies to
mouse-rat chimeras. These antibodies inhibit CCL17 function
even though there is a high degree of similarity between the
rat and mouse proteins; mouse and rat CCL17 share 91%
homology and 83% identity at the amino acid level differing
by only six amino acids. These chimeric antibodies have been
demonstrated to specifically neutralize CCL17 in vitro using
three different functional assays. The antagonistic nature of
the surrogate antibodies in vitromeans they can be utilized to
elucidate the relative contributions of CCL17 and CCL22 in
mouse models of disease.
FIG. 3. Inhibition of CCL17 function is the result of interference with CCR4 signaling. Dose-response curves were run using
purified chimeric antibodies to test for the ability to inhibit b-arrestin recruitment induced by CCR4 signaling. Controls
include anti-CCL17 MAB529 (x) and isotype control MAB006 7) run as positive and negative controls, respectively. Note
that control antibodies were assayed only at the highest antibody concentration, 1mM, and are illustrated as a single point.
Starting antibody concentration for dose curves was 1mM with 1:2 serial dilutions. (A) Antibodies that bind mouse CCL17
only. (B) Antibodies that bind both mouse and human CCL17. Data shown are representative of three experiments.
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Even though both chemokines function through CCR4,
homology between CCL17 and CCL22 is not that high;
however, the most conserved regions in the amino acid se-
quence are proposed to reside within the predicted receptor
binding site.(1,22) For this reason, cross-reactivity with CCL22
was of particular concern as the screening strategy was es-
tablished to identify antibodies that could neutralize CCL17
function, which in turn would likely involve CCR4 interac-
tion. To minimize the possibility of carrying an antibody
forward that binds both proteins, the entire panel of CCL17-
specific antibodies was cross-screened on CCL22, leading to
the identification of one clone. The binding profile of the
MAbs in this panel demonstrates CCL17 selectivity, and the
lack of detectable CCL22 binding suggests that there would
be no interference with CCL22 function. However, additional
analysis of these antibodies using in vitro assays that depend
on CCL22 function would need to be done to confirm that
these two chemokines function independently of each other. If
neutralization of CCL17 function is achieved by blocking in-
teraction with CCR4, this result might have been interpreted
as few, if any, neutralizing antibodies were contained in the
panel. However, we found approximately one-third of the
antibodies tested to be CCL17 neutralizing antibodies (Fig. 5).
It is possible that all of the CCL17 binding antibodies have
some neutralizing capability but the activity is below the de-
tection sensitivity of the screening assay, for example, if they
bind with low affinity. This result does not completely rule
out the possibility that at least some of the antibodies inhibit
CCL17 function by steric hindrance, thus indirectly interfer-
ing with CCR4 interaction rather than blocking the actual
CCR4 binding site on the ligand.
Out of the panel of neutralizing antibodies, only a single
antibody could be confirmed to bind to CCL22 even though
these two chemokines function through the same receptor and
have been reported to compete with each other for CCR4
binding.(1) One explanation for this may be that CCL22 is
produced by activated B cells and dendritic cells (DC) in order
to attract and retain T cell help by local immobilization.(17,23)
CCL17 is also produced by activated B cells and DCs; how-
ever, this chemokine is produced bymany different cell types,
FIG. 4. Calcium mobilization in response to CCL17 signaling is inhibited by chimeric antibodies in a dose-dependent manner.
CCRF-CEM cells were treated in quadruplicate with mouse CCL17 at 2 ng/mL in the presence of each antibody starting at
10mg/mL. Control antibody (asterisk) was run only at the highest concentration of 10mg/mL. Data shown are representative of
two experiments. (A) Antibodies that bind mouse CCL17 only. (B) Antibodies that bind both mouse and human CCL17.
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including both immune and non-immune cells. For example,
macrophages, fibroblasts, keratinocytes, epithelial cells, airway
smoothmuscle cells, andLangerhans cells produceCCL17while
CCL22 is produced only by immune cells.(11,24–26) Inequalities in
the ability of the two chemokines to mediate cell adhesion
in vitro have been reported in that CCL22 tends to improve
cell-cell binding.(4) Perhaps the differential expression pattern
and the superior ability of CCL22 to mediate lymphocyte
adhesion result in localized retention of immune cells, which
could promote an immune response through cell-cell inter-
actions and co-stimulation. Blocking CCL22 function in this
case by inducing an anti-CCL22 antibody response could
potentially disrupt the localized cellular interactions and in-
hibit co-stimulation, resulting in an overall down-regulation
of the response and providing a natural screening system to
eliminate CCL22 specific antibody production.
Cross-screening of the antibodies selected for mouse
CCL17 binding revealed that a subset of antibodies bind hu-
man CCL17 as well as mouse. Mouse CCL17 is also capable of
signaling through human CCR4 even though there is only
66% identify and 83% homology between mouse and human
CCL17.(17) This makes it likely that the amino acids conserved
between the two species are involved in CCR4 binding. If so,
then we could expect that antibodies that neutralize mouse
CCL17 may bind human CCL17 as well. However, when the
panel of CCL17 binding antibodieswas screened for reactivity
to human CCL17, most of the antibodies (84%) were found to
bind only to mouse CCL17, 30% of which were neutralizing
(Fig. 5). The subset of human-mouse cross-reactive antibodies
comprises only 15% of the panel, yet almost 70% of the anti-
bodies in this subset are neutralizing, which suggests that the
epitope(s) recognized by these cross-reactive antibodies is
important for CCL17 function (Fig. 5).
In summary, antibodies that inhibit mouse CCL17 function
but do not bind CCL22 can be generated by immunizing rats
in spite of the high degree of homology with rat CCL17. Even
though mouse CCL17 can signal through human CCR4, only
a fraction of the antibodies described herein bind CCL17 from
both species. These antibodies have been converted from fully
rat antibodies to rat-mouse chimeric antibodies expressed as
mouse IgG1, which makes them ideal for in vivo studies using
mouse models.
FIG. 5. Frequency and specificity overview of anti-CCL17 hybridomas. (A) Frequency of mouse CCL17-specific hybridomas
that bind human CCL17 and mouse CCL22 based on ELISA data from primary screen of hybridomas. All hybridomas were
selected based on mouse CCL17 binding; frequency is expressed as a percentage of all mouse CCL17-specific hybridomas. (B)
Distribution of antagonistic antibodies based on binding specificity. Antagonistic antibodies were identified from a panel of
hybridomas specific for mouse CCL17 using calciummobilization high throughput screen. Data are presented as the percentage
of antibodies that are antagonistic according to binding specificities. The total number of hybridomas for each binding profile
represents 100% of that subgroup with the relative frequency of neutralizing and non-neutralizing hybridomas plotted for each.
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